This document lists 24 publications and presentations by Shaoxia Yu and collaborators from 2005 to the present related to bioanalysis and the development of methods for quantifying drugs and metabolites in biological samples using mass spectrometry. Key areas included using direct analysis in real time (DART) to enable bioanalysis without sample cleanup, microLC approaches for routine bioanalysis, and quantification of monoclonal antibodies and antibody-drug conjugates. Methods were applied to samples from multiple species for late stage drug discovery.
The document summarizes the literature on the value of synovial fluid (SF) assays in diagnosing joint disease. It finds:
1) Traditional SF tests like microbiology, cell counts, and crystal identification lack quality control evidence and show worrying variations between laboratories in reliability.
2) Claims for newer assays like cytology and biochemical markers are mainly anecdotal, and interpretation difficulties limit their clinical use.
3) Overall, SF analysis remains valuable for diagnosing acute arthritis or suspected septic/crystal arthropathy, and in intercritical gout, but quality control and rationalization of tests is needed. Further research is also recommended.
The document provides a summary of Kamal Uddin Zaidi's educational qualifications and professional experience. It details that he holds a PhD in Bioscience from Barkatullah University, Bhopal and has over 10 years of experience in research roles. Currently, he works as a Junior Scientist at the Centre for Scientific Research and Development in Bhopal. The document also lists his publications, areas of research expertise, and participation in conferences.
Viviane Palhares Muniz has over 15 years of experience in molecular biology and biomedical research. She received her PhD from the University of Iowa in Molecular and Cellular Biology in 2012. Since then, she has worked as a postdoctoral scholar at the University of Iowa, developing mouse models to study cancer metabolism, metabolic syndrome, and pancreatic beta-cell proliferation. She has authored or co-authored over 10 publications and presented her research at several conferences. Her expertise includes developing disease models, molecular techniques, and training students.
The document summarizes a 1966 paper by Bauer et al. that standardized the single disk method for antibiotic susceptibility testing. The standardized method consolidated previous descriptions, provided guidelines for use, and yielded reliable results compared to minimum inhibitory concentration tests. It helped clinical microbiologists perform testing more easily. The method's recommendations still provide a valid framework today, though some drugs are obsolete and zone sizes have been modified. The "Kirby-Bauer" disk diffusion method remains the most researched and updated approach used internationally for antibiotic susceptibility testing.
This document provides the educational qualifications and professional experience of Dr. Kamal Uddin Zaidi. It lists his PhD in Bioscience from Barkatullah University, Bhopal as well as his MSc and BSc in Microbiology. It details his 5 years of experience as a Demonstrator and current role as a Research Associate. The document also lists his research publications, seminars attended, skills and research interests in areas such as biotechnology, microbiology and natural product development.
This document provides the educational qualifications and professional experience of Dr. Kamal Uddin Zaidi. It lists his PhD in Bioscience from Barkatullah University, Bhopal as well as his MSc and BSc in Microbiology. It details his 5 years of experience as a Demonstrator and current role as a Research Associate. It also lists several seminars, conferences and publications authored by Dr. Zaidi relating to areas of bioscience, biotechnology and microbiology.
Liu2017 primary antibiotic resistance of helicobacter pylori in chinese patie...Mijail Cjuno
This research note summarizes the results of a 7-year study on antibiotic resistance of Helicobacter pylori in Chinese patients from 13 provinces. The study found:
1) Resistance to metronidazole, clarithromycin, and levofloxacin was high at 78.2%, 22.1%, and 19.2% respectively.
2) Younger patients had lower resistance to clarithromycin, azithromycin, levofloxacin, and moxifloxacin than older patients.
3) Resistance to clarithromycin and amoxicillin increased in more recent years.
4) Geographic location was associated with differences in resistance to metron
This document discusses the use of stem cells for screening endocrine disrupting chemicals (EDCs). It describes how stem cells can be used as a non-animal alternative for drug testing that is less expensive and more efficient than animal models. Specifically, it outlines research using cancer stem cells to test for anti-cancer drugs and EDCs. The document also discusses induced pluripotent stem cells and their potential for modeling human diseases for drug discovery applications and toxicity testing. Finally, it notes that stem cells provide opportunities for basic research into mechanisms of cell behavior and potential applications in regenerative medicine, genetic therapy, and studying stem cell-related diseases and aging.
The document summarizes the literature on the value of synovial fluid (SF) assays in diagnosing joint disease. It finds:
1) Traditional SF tests like microbiology, cell counts, and crystal identification lack quality control evidence and show worrying variations between laboratories in reliability.
2) Claims for newer assays like cytology and biochemical markers are mainly anecdotal, and interpretation difficulties limit their clinical use.
3) Overall, SF analysis remains valuable for diagnosing acute arthritis or suspected septic/crystal arthropathy, and in intercritical gout, but quality control and rationalization of tests is needed. Further research is also recommended.
The document provides a summary of Kamal Uddin Zaidi's educational qualifications and professional experience. It details that he holds a PhD in Bioscience from Barkatullah University, Bhopal and has over 10 years of experience in research roles. Currently, he works as a Junior Scientist at the Centre for Scientific Research and Development in Bhopal. The document also lists his publications, areas of research expertise, and participation in conferences.
Viviane Palhares Muniz has over 15 years of experience in molecular biology and biomedical research. She received her PhD from the University of Iowa in Molecular and Cellular Biology in 2012. Since then, she has worked as a postdoctoral scholar at the University of Iowa, developing mouse models to study cancer metabolism, metabolic syndrome, and pancreatic beta-cell proliferation. She has authored or co-authored over 10 publications and presented her research at several conferences. Her expertise includes developing disease models, molecular techniques, and training students.
The document summarizes a 1966 paper by Bauer et al. that standardized the single disk method for antibiotic susceptibility testing. The standardized method consolidated previous descriptions, provided guidelines for use, and yielded reliable results compared to minimum inhibitory concentration tests. It helped clinical microbiologists perform testing more easily. The method's recommendations still provide a valid framework today, though some drugs are obsolete and zone sizes have been modified. The "Kirby-Bauer" disk diffusion method remains the most researched and updated approach used internationally for antibiotic susceptibility testing.
This document provides the educational qualifications and professional experience of Dr. Kamal Uddin Zaidi. It lists his PhD in Bioscience from Barkatullah University, Bhopal as well as his MSc and BSc in Microbiology. It details his 5 years of experience as a Demonstrator and current role as a Research Associate. The document also lists his research publications, seminars attended, skills and research interests in areas such as biotechnology, microbiology and natural product development.
This document provides the educational qualifications and professional experience of Dr. Kamal Uddin Zaidi. It lists his PhD in Bioscience from Barkatullah University, Bhopal as well as his MSc and BSc in Microbiology. It details his 5 years of experience as a Demonstrator and current role as a Research Associate. It also lists several seminars, conferences and publications authored by Dr. Zaidi relating to areas of bioscience, biotechnology and microbiology.
Liu2017 primary antibiotic resistance of helicobacter pylori in chinese patie...Mijail Cjuno
This research note summarizes the results of a 7-year study on antibiotic resistance of Helicobacter pylori in Chinese patients from 13 provinces. The study found:
1) Resistance to metronidazole, clarithromycin, and levofloxacin was high at 78.2%, 22.1%, and 19.2% respectively.
2) Younger patients had lower resistance to clarithromycin, azithromycin, levofloxacin, and moxifloxacin than older patients.
3) Resistance to clarithromycin and amoxicillin increased in more recent years.
4) Geographic location was associated with differences in resistance to metron
This document discusses the use of stem cells for screening endocrine disrupting chemicals (EDCs). It describes how stem cells can be used as a non-animal alternative for drug testing that is less expensive and more efficient than animal models. Specifically, it outlines research using cancer stem cells to test for anti-cancer drugs and EDCs. The document also discusses induced pluripotent stem cells and their potential for modeling human diseases for drug discovery applications and toxicity testing. Finally, it notes that stem cells provide opportunities for basic research into mechanisms of cell behavior and potential applications in regenerative medicine, genetic therapy, and studying stem cell-related diseases and aging.
Harley Bobnar is a senior at Washington & Jefferson College studying biochemistry with a minor in English. He has conducted extensive research including investigating osteosarcoma metastasis and characterizing tumor microenvironments. His research experiences include an internship at West Virginia University and multiple course-based projects examining topics like apoptosis induction and chromatin remodeling. Bobnar has presented his research at both W&J and WVU. He is proficient in various laboratory techniques and has worked as an organic chemistry teaching assistant.
Abstract— Occupational exposure to formaldehyde (FA) has been related to adverse outcomes. However, a short period of exposure has never been assessed in terms of evaluating DNA. This study conducted on 39 medical students exposed to FA in a university laboratory of human anatomy and aimed to analyze the relationship between FA exposure and DNA damage. The buccal micronucleus cytome assay (BMCyt) was used to evaluate the students at four time points: before FA exposure, after four months of FA exposure, after eight months of FA exposure and after three months without FA exposure (remission period). Pyknotic cells, karyolitic cells, karyorrhetic cells, condensed chromatin, binucleated cells, basal cells differentiated cells, micronucleated cells and nuclear bridges were enumerated. This study shows that FA exposure caused genomic instability in all periods and the remission period was not sufficient to reverse all damage. Thus, prolonged occupational exposure to FA not only causes DNA damage but a shorter exposure period can have the same effect.
This document summarizes recent advances in identifying urinary biomarkers for pediatric renal diseases. It discusses how proteomic techniques have led to the identification of urine as a good source for non-invasive biomarkers. Several studies identified potential biomarkers for ureteropelvic junction obstruction and renal Fanconi syndrome in children, showing promise for urinary proteomics in pediatrics. However, more research is still needed using appropriate validation methods to identify clinically useful biomarkers for other pediatric renal diseases.
This document lists over 40 research articles, reviews, book chapters, and patents authored by G.S. Bisacchi relating to the development of antibacterial drugs and inhibitors of serine proteases and other targets. The publications span several decades and cover topics such as the origins of quinolone antibiotics, efforts to develop new classes of antibacterials, and the synthesis and structure-activity relationships of various inhibitors.
Reading Out the State of the Body and How it Changes Under TherapyLarry Smarr
This document provides a summary of Dr. Larry Smarr's guest lecture on quantifying and monitoring changes in his own body and microbiome over time using various sensors and tests. Some key points:
1) Dr. Smarr reversed the decline in his health by quantifying his nutrition and exercise habits using sensors and making adjustments based on the data.
2) Tests revealed he had chronic inflammation and an autoimmune disease (Crohn's), which he studied further through genetic tests, imaging, and analysis of his microbiome.
3) Dr. Smarr's research showed the potential of precision medicine through quantifying individual health markers and the microbiome over time.
This write up is a proposal and i require contributions from other microbiologist regarding modern methods that could be adopted for the research, I can be contacted at temidayo.elufisan@nacetem.org
The document summarizes the research of Prof. Chieh-Hsi Wu, who focuses on pathological mechanisms involved in restenosis progression and evaluations of bioactive compounds for treating restenosis, hyperlipidemia, and cancer. His laboratory uses genomic and proteomic analyses to identify molecules involved in restenosis development and potential therapeutic targets. He evaluates natural compounds for preventing restenosis and hyperlipidemia.
Lindsay Jordan has over 15 years of experience in the pharmaceutical industry, specializing in immunology techniques including cell culture, molecular biology, and ELISA development. She has worked at Biothera Pharmaceuticals since 2007 where she developed and validated potency assays, authored SOPs, and supported clinical trials. Prior to this, she held positions at 3M Pharmaceuticals and ViroMED Laboratories, optimizing assays and discovering drug mechanisms of action. Jordan has a Bachelor's degree in Biology and is proficient in laboratory techniques and data analysis software. She has authored multiple publications and presentations on topics including beta-glucan immunology and cancer immunotherapy.
Drug efficacy, safety and biologics discoverySean Ekins
The document introduces a book that discusses how emerging technologies are impacting drug discovery and development by enabling more effective prediction of drug efficacy and safety. The book is divided into three parts that cover drug efficacy and safety technologies, biologics technologies, and future perspectives on biological engineering in pharmaceutical research. It aims to educate readers on several key emerging technologies and how they are substantially impacting drug research.
This document summarizes and reviews several research studies on phytochemicals and their relationship to cancer risk and prevention. It discusses cancer statistics such as the most common cancer sites in the US. It also explores topics like nutrigenetics, chemoprevention, and how certain phytochemicals may play a role in reducing cancer risk. Two specific studies are summarized: one reviewing the effectiveness of apple and berry juices in preventing colon cancer, and another investigating the anti-cancer effects of morin, a flavonoid found in mulberry figs, on human leukemia cells.
The laboratory focuses on developing drug delivery systems using biomaterials like hyaluronic acid. A thermosensitive injectable hydrogel was created using nanocomplexes of doxorubicin and hyaluronic acid for local cancer treatment. This hydrogel inhibited cancer cell growth and selectively targeted the lymphatic system due to hyaluronic acid's affinity for the lymphatic system. The lab is also exploring combination therapy delivery systems, such as a thermosensitive hydrogel incorporating doxorubicin and docetaxel-loaded nanoparticles for overcoming drug resistance in tumors.
This document is a resume for Sandra Anderson LaSalle, who has over 20 years of experience in clinical and basic science research. She has worked in a variety of roles including as a research scientist at Merck, Pfizer, and various universities. Her experience includes laboratory management, product development, clinical research, and teaching. She has advanced knowledge in microbiology and experience in fields like oncology, diabetes, and female reproduction.
The document provides information on several professors and their research areas at College of Pharmacy. It includes the names and areas of research for Professors Jing-Ping Liou, Chieh-Hsi Wu, Shawn Hsiang-Yin Chen, Wei-Chiao Chang, Jen-Ai Lee, David Hui-Wen Cheng, and Tzu-Hua Wu. The research areas include medicinal and organic chemistry, cardiovascular and cancer pharmacology, clinical pharmacy, pharmacogenomics, bioanalytical chemistry, pharmaceutical management and regulatory affairs, and clinical pharmacy and therapeutics. It also lists some representative publications for each professor.
Robert Pesich_PAVA_Stanford Resume v. 8_22_16Robert Pesich
Robert Pesich has extensive experience managing laboratory operations and research projects. He has overseen the daily activities of 25 researchers at Stanford University and the Palo Alto VA, including managing budgets, equipment, and regulatory compliance. Pesich has specialized skills in tissue sample processing, gene expression analysis, and bioinformatics. He has authored several publications characterizing gene expression profiles in normal and diseased tissues. Currently, Pesich also serves as President of a poetry non-profit organization.
This study investigated the potential influence of pre-exposure prophylaxis (PrEP) on risk behavior in an HIV prevention program in Houston, Texas. Data was collected from 96 patients at baseline and 6 months through surveys and medical chart reviews. The results showed that 36% reported decreased condom use at 6 months, but this was not associated with gender, race, ethnicity, or PrEP use. Patients with an HIV positive partner were less likely to decrease condom use, as were those with the same or fewer number of sexual partners over time. While 16% reported an increased number of partners at 6 months, PrEP use did not predict this increase in risk behavior. The study concluded that in a real-world clinical setting
Sijin Wu has a Ph.D. in Biochemical Engineering and extensive experience in computational biology and computer-aided drug design. His research focuses on protein modeling, molecular dynamics simulation, and virtual screening. He has authored or co-authored over 15 publications and developed databases on proteins with targetable cysteines and cancer stem cell therapeutic targets. Wu seeks postdoctoral opportunities to further his work in these fields.
Kristin M. Obrochta has a Ph.D. in Comparative Biochemistry from UC Berkeley and is currently a postdoctoral associate at the Buck Institute for Research on Aging. Her research focuses on genetic diseases, neuroscience, metabolism, cancer, and aging. Her dissertation research at UC Berkeley characterized novel regulation of retinoic acid synthesis by the transcription factor FoxO1 in the liver. She has published papers on quantifying retinaldehyde and the effects of diet and strain on mouse retinoid concentrations.
Toward a reliable and interoperable public repository for natural product-dru...Richard Boyce, PhD
A poster presented at the 2017 Annual Symposium of the American Medical Informatics Association (AMIA 2017). November 04- 08, 2017. Washington, DC. USA
Good Health: The Impact of Space Science on Precision Medicinemtnadmin
The panel discussion focused on how space science and research conducted aboard the International Space Station (ISS) can advance precision medicine on Earth. Julie Robinson discussed how NASA research on the ISS provides valuable data on human health and disease that contributes to precision medicine. Steven Steinhubl discussed how wearable sensors and digital biomarkers can continuously monitor physiological changes in individuals and populations to better understand health and disease. Joan McGowan discussed the history of NIH-funded life science research aboard spacecraft and the ISS, and how this research contributes to public health on Earth. The panel concluded by discussing the new Precision Medicine Initiative announced by President Obama which aims to accelerate biomedical research and turn precision medicine into a reality.
Mohan Vivekanandan has 5 years of experience in bioanalytical assay development and quality control for biotherapeutics and vaccines. He has a PhD in Biochemistry and expertise in protein characterization, stability testing, method development and validation. His most recent role was as a Research Scientist at Theragen Biologics where he developed ELISA and other assays to characterize a novel Fab protein. He is looking for a challenging career in a progressive organization.
This curriculum vitae summarizes Robert B. Abel's education and professional experience. He has a Ph.D. in Statistics from Ohio State University and over 25 years of experience as a statistical consultant and biostatistician for pharmaceutical and biotech companies. His work has involved providing statistical support for clinical trials and product development across various therapeutic areas. He has authored over 30 publications and presentations related to biostatistics and clinical research.
This document provides a summary of Michael L. Avery's education and professional experience. He holds a BS and BGS in Cell Biology and Microbiology from the University of Kansas, and an MA in Microbiology. His experience includes over 13 years in analytical sciences and process development at Amgen, analytical chemistry research at Sigma-Aldrich Biosciences, and various roles supporting drug development and preclinical studies at 3M Pharmaceuticals and Quintiles. He has extensive experience in analytical techniques such as HPLC, CE, LC/MS, and related methods for characterizing proteins and small molecules.
Harley Bobnar is a senior at Washington & Jefferson College studying biochemistry with a minor in English. He has conducted extensive research including investigating osteosarcoma metastasis and characterizing tumor microenvironments. His research experiences include an internship at West Virginia University and multiple course-based projects examining topics like apoptosis induction and chromatin remodeling. Bobnar has presented his research at both W&J and WVU. He is proficient in various laboratory techniques and has worked as an organic chemistry teaching assistant.
Abstract— Occupational exposure to formaldehyde (FA) has been related to adverse outcomes. However, a short period of exposure has never been assessed in terms of evaluating DNA. This study conducted on 39 medical students exposed to FA in a university laboratory of human anatomy and aimed to analyze the relationship between FA exposure and DNA damage. The buccal micronucleus cytome assay (BMCyt) was used to evaluate the students at four time points: before FA exposure, after four months of FA exposure, after eight months of FA exposure and after three months without FA exposure (remission period). Pyknotic cells, karyolitic cells, karyorrhetic cells, condensed chromatin, binucleated cells, basal cells differentiated cells, micronucleated cells and nuclear bridges were enumerated. This study shows that FA exposure caused genomic instability in all periods and the remission period was not sufficient to reverse all damage. Thus, prolonged occupational exposure to FA not only causes DNA damage but a shorter exposure period can have the same effect.
This document summarizes recent advances in identifying urinary biomarkers for pediatric renal diseases. It discusses how proteomic techniques have led to the identification of urine as a good source for non-invasive biomarkers. Several studies identified potential biomarkers for ureteropelvic junction obstruction and renal Fanconi syndrome in children, showing promise for urinary proteomics in pediatrics. However, more research is still needed using appropriate validation methods to identify clinically useful biomarkers for other pediatric renal diseases.
This document lists over 40 research articles, reviews, book chapters, and patents authored by G.S. Bisacchi relating to the development of antibacterial drugs and inhibitors of serine proteases and other targets. The publications span several decades and cover topics such as the origins of quinolone antibiotics, efforts to develop new classes of antibacterials, and the synthesis and structure-activity relationships of various inhibitors.
Reading Out the State of the Body and How it Changes Under TherapyLarry Smarr
This document provides a summary of Dr. Larry Smarr's guest lecture on quantifying and monitoring changes in his own body and microbiome over time using various sensors and tests. Some key points:
1) Dr. Smarr reversed the decline in his health by quantifying his nutrition and exercise habits using sensors and making adjustments based on the data.
2) Tests revealed he had chronic inflammation and an autoimmune disease (Crohn's), which he studied further through genetic tests, imaging, and analysis of his microbiome.
3) Dr. Smarr's research showed the potential of precision medicine through quantifying individual health markers and the microbiome over time.
This write up is a proposal and i require contributions from other microbiologist regarding modern methods that could be adopted for the research, I can be contacted at temidayo.elufisan@nacetem.org
The document summarizes the research of Prof. Chieh-Hsi Wu, who focuses on pathological mechanisms involved in restenosis progression and evaluations of bioactive compounds for treating restenosis, hyperlipidemia, and cancer. His laboratory uses genomic and proteomic analyses to identify molecules involved in restenosis development and potential therapeutic targets. He evaluates natural compounds for preventing restenosis and hyperlipidemia.
Lindsay Jordan has over 15 years of experience in the pharmaceutical industry, specializing in immunology techniques including cell culture, molecular biology, and ELISA development. She has worked at Biothera Pharmaceuticals since 2007 where she developed and validated potency assays, authored SOPs, and supported clinical trials. Prior to this, she held positions at 3M Pharmaceuticals and ViroMED Laboratories, optimizing assays and discovering drug mechanisms of action. Jordan has a Bachelor's degree in Biology and is proficient in laboratory techniques and data analysis software. She has authored multiple publications and presentations on topics including beta-glucan immunology and cancer immunotherapy.
Drug efficacy, safety and biologics discoverySean Ekins
The document introduces a book that discusses how emerging technologies are impacting drug discovery and development by enabling more effective prediction of drug efficacy and safety. The book is divided into three parts that cover drug efficacy and safety technologies, biologics technologies, and future perspectives on biological engineering in pharmaceutical research. It aims to educate readers on several key emerging technologies and how they are substantially impacting drug research.
This document summarizes and reviews several research studies on phytochemicals and their relationship to cancer risk and prevention. It discusses cancer statistics such as the most common cancer sites in the US. It also explores topics like nutrigenetics, chemoprevention, and how certain phytochemicals may play a role in reducing cancer risk. Two specific studies are summarized: one reviewing the effectiveness of apple and berry juices in preventing colon cancer, and another investigating the anti-cancer effects of morin, a flavonoid found in mulberry figs, on human leukemia cells.
The laboratory focuses on developing drug delivery systems using biomaterials like hyaluronic acid. A thermosensitive injectable hydrogel was created using nanocomplexes of doxorubicin and hyaluronic acid for local cancer treatment. This hydrogel inhibited cancer cell growth and selectively targeted the lymphatic system due to hyaluronic acid's affinity for the lymphatic system. The lab is also exploring combination therapy delivery systems, such as a thermosensitive hydrogel incorporating doxorubicin and docetaxel-loaded nanoparticles for overcoming drug resistance in tumors.
This document is a resume for Sandra Anderson LaSalle, who has over 20 years of experience in clinical and basic science research. She has worked in a variety of roles including as a research scientist at Merck, Pfizer, and various universities. Her experience includes laboratory management, product development, clinical research, and teaching. She has advanced knowledge in microbiology and experience in fields like oncology, diabetes, and female reproduction.
The document provides information on several professors and their research areas at College of Pharmacy. It includes the names and areas of research for Professors Jing-Ping Liou, Chieh-Hsi Wu, Shawn Hsiang-Yin Chen, Wei-Chiao Chang, Jen-Ai Lee, David Hui-Wen Cheng, and Tzu-Hua Wu. The research areas include medicinal and organic chemistry, cardiovascular and cancer pharmacology, clinical pharmacy, pharmacogenomics, bioanalytical chemistry, pharmaceutical management and regulatory affairs, and clinical pharmacy and therapeutics. It also lists some representative publications for each professor.
Robert Pesich_PAVA_Stanford Resume v. 8_22_16Robert Pesich
Robert Pesich has extensive experience managing laboratory operations and research projects. He has overseen the daily activities of 25 researchers at Stanford University and the Palo Alto VA, including managing budgets, equipment, and regulatory compliance. Pesich has specialized skills in tissue sample processing, gene expression analysis, and bioinformatics. He has authored several publications characterizing gene expression profiles in normal and diseased tissues. Currently, Pesich also serves as President of a poetry non-profit organization.
This study investigated the potential influence of pre-exposure prophylaxis (PrEP) on risk behavior in an HIV prevention program in Houston, Texas. Data was collected from 96 patients at baseline and 6 months through surveys and medical chart reviews. The results showed that 36% reported decreased condom use at 6 months, but this was not associated with gender, race, ethnicity, or PrEP use. Patients with an HIV positive partner were less likely to decrease condom use, as were those with the same or fewer number of sexual partners over time. While 16% reported an increased number of partners at 6 months, PrEP use did not predict this increase in risk behavior. The study concluded that in a real-world clinical setting
Sijin Wu has a Ph.D. in Biochemical Engineering and extensive experience in computational biology and computer-aided drug design. His research focuses on protein modeling, molecular dynamics simulation, and virtual screening. He has authored or co-authored over 15 publications and developed databases on proteins with targetable cysteines and cancer stem cell therapeutic targets. Wu seeks postdoctoral opportunities to further his work in these fields.
Kristin M. Obrochta has a Ph.D. in Comparative Biochemistry from UC Berkeley and is currently a postdoctoral associate at the Buck Institute for Research on Aging. Her research focuses on genetic diseases, neuroscience, metabolism, cancer, and aging. Her dissertation research at UC Berkeley characterized novel regulation of retinoic acid synthesis by the transcription factor FoxO1 in the liver. She has published papers on quantifying retinaldehyde and the effects of diet and strain on mouse retinoid concentrations.
Toward a reliable and interoperable public repository for natural product-dru...Richard Boyce, PhD
A poster presented at the 2017 Annual Symposium of the American Medical Informatics Association (AMIA 2017). November 04- 08, 2017. Washington, DC. USA
Good Health: The Impact of Space Science on Precision Medicinemtnadmin
The panel discussion focused on how space science and research conducted aboard the International Space Station (ISS) can advance precision medicine on Earth. Julie Robinson discussed how NASA research on the ISS provides valuable data on human health and disease that contributes to precision medicine. Steven Steinhubl discussed how wearable sensors and digital biomarkers can continuously monitor physiological changes in individuals and populations to better understand health and disease. Joan McGowan discussed the history of NIH-funded life science research aboard spacecraft and the ISS, and how this research contributes to public health on Earth. The panel concluded by discussing the new Precision Medicine Initiative announced by President Obama which aims to accelerate biomedical research and turn precision medicine into a reality.
Mohan Vivekanandan has 5 years of experience in bioanalytical assay development and quality control for biotherapeutics and vaccines. He has a PhD in Biochemistry and expertise in protein characterization, stability testing, method development and validation. His most recent role was as a Research Scientist at Theragen Biologics where he developed ELISA and other assays to characterize a novel Fab protein. He is looking for a challenging career in a progressive organization.
This curriculum vitae summarizes Robert B. Abel's education and professional experience. He has a Ph.D. in Statistics from Ohio State University and over 25 years of experience as a statistical consultant and biostatistician for pharmaceutical and biotech companies. His work has involved providing statistical support for clinical trials and product development across various therapeutic areas. He has authored over 30 publications and presentations related to biostatistics and clinical research.
This document provides a summary of Michael L. Avery's education and professional experience. He holds a BS and BGS in Cell Biology and Microbiology from the University of Kansas, and an MA in Microbiology. His experience includes over 13 years in analytical sciences and process development at Amgen, analytical chemistry research at Sigma-Aldrich Biosciences, and various roles supporting drug development and preclinical studies at 3M Pharmaceuticals and Quintiles. He has extensive experience in analytical techniques such as HPLC, CE, LC/MS, and related methods for characterizing proteins and small molecules.
This curriculum vitae summarizes the qualifications of Alexander Brown, Ph.D. He received his Ph.D. in Cell & Molecular Biology from the University of Rhode Island in 2014. Since then, he has worked as a postdoctoral researcher at the University of Illinois where he has developed genome engineering strategies. He has extensive experience in molecular biology techniques and has authored several publications. Brown has also held teaching positions where he has instructed courses in biochemistry and microbiology.
Judith Luber-Narod has extensive experience in cellular and molecular pharmacology, in vitro toxicology, neuroimmunology, autoimmunity, oncology, and engineering. She has held positions as an industrial scientist, academic scientist, professor, and high school teacher. Her background includes research in various areas including neuroscience, immunology, toxicology, and oncology. She has authored several publications and holds patents in areas related to her work.
Roland Matsouaka is an Assistant Professor of Biostatistics and Bioinformatics at Duke University Medical Center. He received his PhD in Biostatistics from Harvard School of Public Health in 2012. His research interests include model selection and validation, risk adjustment, biomarker evaluation, and causal inference methods. He has over 10 publications in peer-reviewed journals and has served as a co-investigator on several grants related to cardiovascular disease.
1. Page 1 of 4
SELECTED PUBLICATION
1. Shaoxia Yu, Jayaprakasam Bolleddula, Charles Locuson, Robert Griffin, Cindy Xia, Jing-Tao Wu,
Swapan Chowdhury "Prediction of Human Fg using Half-life Determined in Intestinal Microsomes”
In preparation.
2. Ling Xu, Bingli Ma, Shaoxia Yu, Cindy Xia and Jing-tao Wu “The Use of a Rapid Mass
Spectrometry Based Method for the Quantification of CYP 3A4 Protein Directly from Hepatocyte
Cell Lysate for CYP Induction Studies” Bioanalysis 2014, 6 (11).
3. Justin Gordon, Mike Johnson, Jing-Tao Wu, Shaoxia Yu* “A Simplified Approach for the
Simultaneous Qualification of Bioanalytical Methods for Multiple Species at Late Discovery Stage”
Bioanalysis 2012, 4(9).
4. Elizabeth Crawford, Justin Gordon, Jing-tao Wu, Brian Musselman, Ray Liu, Shaoxia Yu “Direct
Analysis in Real Time Coupled with Dried Spot Sampling for Bioanalysis in a Drug Discovery
Setting” Bioanalysis 2011, 3(11).
5. Matthew O. Duffey *, Ruth Adams, Christopher Blackburn, Ryan W. Chau, Susan Chen, Katherine
M. Galvin,Khristofer Garcia, Alexandra E. Gould, Paul D. Greenspan, Sean Harrison, Shih-Chung
Huang, Mi-Sook Kim,Bheemashankar Kulkarni, Steven Langston, Jane X. Liu, Li-Ting Ma, Saurabh
Menon, Masayuki Nagayoshi,R. Scott Rowland, Tricia J. Vos, Tianlin Xu, Johnny J. Yang, Shaoxia
Yu, “Discovery and optimization of pyrazoline compounds as B-Raf inhibitors” Bioorganic &
Medicinal Chemistry Letters 20 (2010) 4800–4804.
6. Shaoxia Yu ,Elizabeth Crawford, Joe Tice, Brian Musselman, Jing-Tao Wu “Bioanalysis without
Sample Cleanup or Chromatography: The Use of Direct Analysis in Real Time (DART) Ionization
Mass Spectrometry for the Direct Quantitation of Drugs in Biological Fluids” Analytical Chemistry,
2009, 81, 193–202.
7. Shaoxia Yu, Shelly Li, Hua Yang, Jing-tao Wu, Frank Lee, and Mark Qian “A Novel LC/MS/MS
Based Depletion Method for Measuring Red Blood Cell Partitioning of Pharmaceutical Compounds
in Drug Discovery” Rapid Communications in Mass Spectrometry, 2005; 19:250-254.
SELECTED PRESENTATIONS
1. Shaoxia Yu, Jayaprakasam Bolleddula, Charles Locuson, Robert Griffin, Cindy Xia, Jing-Tao Wu,
Swapan Chowdhury ‘Prediction of Human Fg using Half-life Determined in Intestinal Microsomes’
MDO 2016, Davis CA.
2. Ling Xu, Shaoxia Yu, Jing-Tao Wu, Mark Qian “Evaluation of Different Immunocapture Platforms
for Antibody-Conjugated Drug Quantification” The 64th
ASMS 2016 San Antonio, TX, USA.
3. Linlin Dong; Michael Johnson; Mark Qian; Shaoxia Yu “An Ion-pairing Strategy to Overcome PEG-
400 Caused Matrix Effect in Routine Drug Discovery Blood Sample Analysis” The 63th
ASMS 2015
St. Louis, MO.
4. Ling Xu, Shaoxia Yu, Jing-Tao Wu, Mark Qian “An LC/MS/MS Based Strategy for Quantification
of Monoclonal Antibodies and Antibody-conjugated Drugs for Developing Antibody Drug
Conjugates” CPSA 2015, Shang Hai, China.
5. Shaoxia Yu; Linlin Dong; Mike Johnson; Mark Qian; Chuang Lu “Development and Qualification of
a Method for Quantification of NAD in Biological Matrices” The 9th
WRIB, 2015, Miami, FL, USA
6. Susan Chen, Mark Qian, Shaoxia Yu “Chasing a “Ghost Peak”: Lessons Learned from a
Bioanalytical Method Qualification” APA, 2014 Boston.
7. Michael Johnson, Swapan Chowdhury, Patrick Kirby, Craig Fisher, Andy Lynn Jing-Tao Wu,
Shaoxia Yu “Development and Qualification of a Method for Quantitative Determination of Multiple
Bile Acids with microLC/MS/MS” the 62th
ASMS 2014 Baltimore, MN, USA.
8. Michael Johnson, Justin Gordon, Jing-Tao Wu, Shaoxia Yu “Evaluation of a micro liquid
chromatography approach for routine bioanalysis of small molecules” APA 2013 Boston.
2. Page 2 of 4
9. Justin Gordon, Ling Xu, Mike Johnson, Dmitry Blinder, Wendy Smith, Jing-Tao Wu, Shaoxia Yu
“An Investigation into the Lack of Protein Binding Equilibrium for Acidic Drug in Mouse Plasma”
APA 2013, Boston.
10. Benjamin Ngo, Shaoxia Yu, Ling Xu, Swapan Chowdhury, Jing-Tao Wu, Mike S. Lee, Gary
Valaskovic “The Design and Characterization of a Novel Ultra-low Flow Nanoelectrospray Device
for Metabolite Quantitation” The 61th ASMS 2013 Minneapolis, MN, USA.
11. Ling Xu, Shaoxia Yu, Jing-Tao Wu, “Novel High-throughput Bioanalysis for Basic Drug Candidates
Formulated in PEG”. Poster presentation at the 61th
ASMS Minneapolis, Minnesota,2013
12. Michael Johnson, Justin Gordon, Martin Paton, Jing-Tao Wu, Shaoxia Yu* “Elimination of carry-
over utilizing CTC HTS-xt in LC-MS analysis of biological samples” poster presentation at the 60th
ASMS 2012 Vancouver, Canda.
13. Justin Gordon, Mike Johnson, Jing-Tao Wu, Phil Geovanos, Shaoxia Yu* “Multi-Species
Simultaneous Qualification of Bioanalytical Methods for Compounds at Late Drug Discovery Stage”
poster presentation at the 60th
ASMS 2012 Vancouver, Canda.
14. Benjamin Ngo; Shaoxia Yu; Mike S. Lee; Jing-Tao Wu; Gary Valaskovic “Fundamental
Characteristics of Small Molecule Analysis using Ultra Low Dynamic Flow Nanospray1; poster
presentation at the 59th
ASMS 2011 Denver, CO .
15. Justin Gordon, Wu JT, Yu S. “One Stone Five Birds: A Simplified Approach for Non-GLP
Bioanalytical Method Qualification with Multiple Species. APA 2011, Boston.
16. Justin Gordon; Elizabeth Crawford; Jing-Tao Wu; Brian Musselman; Ming-xiang Liao; Bei-Ching
Chuang; Cindy Xia; David Ho; Lily Li; Shaoxia Yu* “Quantitative Analysis of Dried Blood Spots
by DART (Direct Analysis in Real Time) /MS/MS without Sample Preparation”, oral presentation
at 58th ASMS 2010 , Salt lake City, UT, USA.
17. Elizabeth Crawford, Shaoxia Yu, Lawrence Cohen, Justin Gordon, Brian Musselman, Jing-Tao Wu
“Eliminating Method Development, Sample Preparation and Chromatographic Separations in High-
Throughput Bioanalysis Using DART on an Enhanced Resolution Triple-Quadrupole Mass
Spectrometer”, oral presentation at 57th ASMS 2009, Philadelphia, PA.
18. Yu, S., Crawford, E., Tice, J., Musselman, B., and Wu, J-T., “Improving the Reproducibility and
Practicability of DART for the Direct Quantification of Drugs in Biological Fluids” oral
presentation at 56th ASMS 2008, Denvor, CO, USA.
19. Shaoxia Yu “Enabling Bioanalysis Without Sample Cleanup” oral presentation 2008 Vendor user
meeting, Denvor, CO.
20. Yu, S. X., Musselman, B., Tice, J., Crawford, E., and Wu, J-T.,” Bioanalysis without Sample
Cleanup or Chromatography: The Evaluation and Initial Implementation of DART Ionization Mass
Spectrometry for the Quantification of Drugs in Biological Matrixes” poster presentation at 55th
ASMS 2007 Indianapolis, IN, USA.
21. Shaoxia Yu, Shelly Li, Hua Yang, Jing-tao Wu, Frank Lee, and Mark Qian “A Fast LC/MS/MS
Screening Method for Evaluating Red Blood Cell Partitioning of Small Molecule Drugs” , poster
presentation at the 52th ASMS, 2004, Nashville, TN.
22. Shaoxia Yu, Jing-tao Wu, Mark Qian, “New Method Development for Rat Fat Tissue Sample
Preparation in Pharmacokinetics Study by LC-MS-MS”, poster presentation at The 20th
Montreux
LC/MS Symposium 2003, Savannah, GA, USA.
23. Lily Li, Ru Wei, Shaoxia Yu, Christa Beauregard, Arthur Rugg, Roger Wiegand, (Cereon); Sharon
Lu, Elizebth Baronas and Frank Hsieh (Millennium), “High Throughput Metabolic Profiling
Development Using Mass Spectrometric Techniques”; poster presentation at the 50th
ASMS , 2002.
Orlando, FL.
24. Shaoxia Yu, Arthur Rugg, and Lily Li (Cereon); Sharon Lu and Frank Hsieh (Millennium), “High
Throughput Analysis of Amino Acids in Biological Matrixes”, poster presentation at the 49th
ASMS
2001 Chicago IL.